Clinical Trial Search

Primary: Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 Hours — 80.0; 93.0; 39.3 percentage of participants

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Parasitological Success (MITT) — 66; 28; 4; 43 participants — p=<0.005

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Freedom From Seizure — 7 individuals

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001

Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L

Primary: Number of Participants Who Died — 5; 5; 5 Participants

Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05

Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Emax — 0.201 Maximum clearance rate (1/hour)

Primary: Infection Rate — 5; 6; 3; 0 Participants

Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants

Primary: Incidence of Clinical Malaria Per Patient Year — 0.04; 3.05; 1.36 episodes/patient year

Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants

Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106

Primary: Prevalence of Placental Malaria — 49; 30; 26 Participants

Primary: Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 11; 13; 15; 14 Participants

Primary: Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose — 14; 10 participants — p=0.17

Primary: Change in Percentage of Parasites Detected at 48 Hours — 99.998 percentage of parasite change

Primary: Incidence of Clinical Episodes of Malaria — 304.8; 278.2; 113.3 No. of events/1000 person years at risk

Primary: Emax — 0.35 Maximum clearance rate (1/hour)

Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat…

Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants

Primary: Activity of SJ733 Administered Orally on Clearance of P. Falciparum Blood Stage Parasites From the Blood in Healthy Subjects (Men and WNCBP) — 172; 11551 Parasite…

Primary: Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs — 9; 0; 1 Participants